Trypan blue staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different microbicide formulations

Sexually Transmitted Diseases

Volumn 39, Issue 9, 2012, Pages 710-712

  Hemmerling, Anke ^a   Harrison, William G ^a   Brown, Joelle Morgan ^a,b   Moscicki, Barbara ^a   Oziemkowska, Maria ^a   Bukusi, Elizabeth A ^c   Cohen, Craig R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

GEL FILLED HTI POLYPROPYLENE; LOW DENSITY POLYETHYLENE; MICROBICIDE; POLYPROPYLENE; TRYPAN BLUE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXPOSURE; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PELVIC EXAMINATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POWDER; STAINING; VAGINA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, INTRAVAGINAL; ADULT; ANTI-INFECTIVE AGENTS; COLORING AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MEDICATION ADHERENCE; POLYETHYLENE; POLYPROPYLENES; STAINING AND LABELING; SURFACE PROPERTIES; TRYPAN BLUE; VAGINA;

EID: 84865454559     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3182641f08     Document Type: Article

References (15)

1. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carra-guard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1977-1987.
2. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359:463-472.
3. Padian NS, van der Straten A, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: A randomised controlled trial. Lancet 2007; 370: 251-261.
4. Turner AN, De Kock AE, Meehan-Ritter A, et al. Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews. J Clin Epidemiol 2009; 62:759-765.
5. Wallace AR, Thorn M, Maguire RA, et al. Assay for establishing whether microbicide applicators have been exposed to the vagina. Sex Transm Dis 2004; 31:465-468.
6. Hogarty K, Kasowitz A, Herold BC, et al. Assessment of adherence to product dosing in a pilot microbicide study. Sex Transm Dis 2007; 34:1000-1003.
7. Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception 2007; 76:53-56.
8. Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis 2009; 36:1000-1003.
9. Katzen LL, Fernández-Romero JA, Sarna A, et al. Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis 2011; 38:1050-1055.
10. Furuyima A. Relationship between molecular characteristics and physical properties of linear low density polyethylenes. Pure Appl Chem 1985; 57:823-832.
11. Cohen CR, Brown J, Moscicki AB, et al. A phase i randomized placebo controlled trial of the safety of 3% SPL7013 gel (Viva-Gel) in healthy young women administered twice daily for 14 days. PLoS One 2011; 6:e16258.
12. Hemmerling A, Harrison W, Schroeder A, et al. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. Sex Transm Dis 2009; 36:564-569.
13. Hemmerling A, Harrison W, Schroeder A, et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vagi-nosis. Sex Transm Dis 2010; 37:745-750.
14. Mauck CK. Biomarkers for semen exposure. Sex Transm Dis 2009; 36(suppl 3):S81-S83.
15. Mauck CK, van der Straten A. Using objective markers to assess participant behavior in HIV prevention trials of vaginal microbi-cides. J Acquir Immune Defic Syndr 2008; 49:64-69.